Domestic price of Nivolumab

Nivolumab (Nivolumab) is an immune checkpoint inhibitor, also known as an anti-PD-1 antibody, which is a drug used for cancer treatment. Nivolumab inhibits the binding of the immune checkpoint protein PD-1 and its ligand PD-L1 in the body, thereby activating the patient's own immune system to attack the tumor. This drug can enhance the patient's immune response, promote the death of tumor cells, and extend the patient's survival.

Pretreatment workup with nivolumab includes an extensive clinical history and physical examination. This includes a thorough baseline clinical assessment of all organ systems. Prior to treatment, recent imaging studies are necessary to monitor treatment effects. Acute and subclinical infections (Mycobacterium tuberculosis, hepatitis B and C viruses, human immunodeficiency virus, cytomegalovirus) should be excluded by serologic testing. Nivolumab has been approved for the treatment of a variety of malignant tumors, including non-small cell lung cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, etc. However, this drug may cause some side effects, such as fatigue, nausea, rash, immune-related toxicities, etc. The use of nivolumab needs to be under the guidance of a doctor and used strictly in accordance with the doctor's instructions.

The generic drug nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. The price of 40mg/4ml box may be around 4,000 yuan, and the price of 100mg/10ml box may be around 7,000 yuan. The Turkish version of the nivolumab antigenic drug marketed overseas may cost more than RMB 2,000 per box of 40 mg/4ml, and may cost more than RMB 5,000 per box of 100 mg/10 ml (the price may fluctuate due to exchange rates). There is currently no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.